These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 28993275)

  • 1. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
    Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
    BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
    Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
    Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
    Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
    Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
    Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
    Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune characterization of breast cancer metastases: prognostic implications.
    Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
    Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.
    He TF; Yost SE; Frankel PH; Dagis A; Cao Y; Wang R; Rosario A; Tu TY; Solomon S; Schmolze D; Mortimer J; Lee P; Yuan Y
    PLoS One; 2020; 15(3):e0229955. PubMed ID: 32150594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes and CD8
    Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.